| Literature DB >> 33182667 |
David A Gómez-Beltrán1, David Villar1, Sara López-Osorio1, Duncan Ferguson2, Laura K Monsalve1, Jenny J Chaparro-Gutiérrez1.
Abstract
The susceptibility to antimicrobials of bacterial isolates from dogs (n = 1256) and cats (n = 94) was retrospectively evaluated in a veterinary diagnostic laboratory over a 4-year period (2016-2019). Out of 1316 isolates in dogs, 771 were Staphylococcus spp. distributed as follows: Staph. pseudointermedius (n = 406), Staph. intermedius (n = 160), Staph. aureus (n = 104), and Staph. coagulase-negative (n = 101). In common, all Staphylococcus spp. showed a high prevalence (20-50%) of resistance to ampicillin, cephalosporin, enrofloxacin, gentamicin, tetracycline, and trimethoprim-sulfonamide, but a low prevalence (1-10%) of resistance to amoxicillin-clavulanate. With regards to the other families of bacteria, the number of antimicrobials for which resistance was high (>20%) in dogs was: Enterobacteriaceae (7/12), Enterococcus spp. (10/16), E. coli (11/15), Pseudomonas spp. (10/13), and Streptococcus spp. (4/9). For urinary tract infections caused by E. coli or Enterobacteriaceae (Klebsiella spp., Proteus spp.), amikacin and florfenicol were the only drugs that demonstrated 100% in vitro efficacy. Multi-drug resistance was observed in 18.7% (246/1316) and 22% (21/97) of the isolates from dogs and cats, respectively. Except for Pseudomonas spp., known for intrinsic resistance, resistance in other bacteria was likely attributed to high selection pressure. In conclusion, empirical antimicrobial use cannot be recommended to treat most common infections, and selection should be based on results from susceptibility testing.Entities:
Keywords: Colombia; antimicrobial resistance; cats; dogs; multidrug resistance
Year: 2020 PMID: 33182667 PMCID: PMC7712406 DOI: 10.3390/vetsci7040173
Source DB: PubMed Journal: Vet Sci ISSN: 2306-7381
Bacterial isolates from clinical samples from dogs submitted to the Diagnostic Laboratory of the Faculty of Agrarian Sciences, University of Antioquia (2016–2019).
| Clinical Samples |
|
|
|
| Others f | ||||
|---|---|---|---|---|---|---|---|---|---|
| % (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | ||
| Ear | 667 | 9.1 (7.2–11.6) | 7.3 (5.6–9.6) | 3.3 (2.2–4.9) | 7.9 (6.1–10.29 | 6.7 (5.0–8.9) | 64.0 (60.3–67.6) | 0.9 (0.4–1.9) | 0.6 (0.2–1.5) |
| Wound | 240 | 8.3 (5.5–12.5) | 5.0 (2.9–8.5) | 4.6 (2.5–8.0) | 4.2 (2.3–7.5) | 10.4 (7.1–14.9) | 65.0 (58.8–70.7) | 1.3 (0.4–3.6) | 1.3 (0.40–3.6) |
| Urine | 226 | 34.1 (28.2–40.5) | 5.3 (3.1–9.0) | 46.5 (40.1–52.9) | 2.2 (0.9–5.0) | 1.8 (0.7–4.5) | 9.7 (6.5–14.3) | 0.4 (0.1–2.5) | 0 (0–1.7) |
| Skin | 45 | 2.2 (0.4–11.6) | 4.4 (1.2–14.8) | 2.2 (0.4–11.6) | 4.4 (1.2–14.8) | 33.3 (21.3–47.9) | 48.9 (35.0–63.0) | 2.2 (0.4–11.6) | 2.2 (0.4–11.6) |
| Nasal cavity | 34 | 17.6 (8.3–33.5) | 11.8 (4.7–26.6) | 14.7 (6.4–30.1) | 0 (0–10.2) | 2.9 (0.52–14.9) | 35.3 (21.5–52.1) | 5.9 (1.6–19.1) | 11.8 (4.7–26.6) |
| Abscess | 18 | 5.6 (1.0–25.7) | 22.2 (9.0–45.2) | 22.2 (5.8–39.2) | 11.1 (3.1–32.8) | 0 (0–17.6) | 38.9 (20.3–61.4) | 0 (0–17.6) | 5.6 (1.0–25.7) |
| Eyes | 15 | 6.7 (1.19–29.8) | 0 (0–20.4) | 20.0 (7.0–45.2) | 6.7 (1.2–29.8) | 26.7 (10.9–51.9) | 33.3 (15.2–58.3) | 6.7 (1.2–29.8) | 0 (0–20.4) |
| Surgical | 11 | 0 (0–25.9) | 9.1 (1.6–37.7) | 27.3 (9.7–56.5) | 27.3 (9.7–56.5) | 18.2 (5.1–47.7) | 18.2 (5.1–47.7) | 0 (0–25.9) | 0 (0–25.9) |
aEnterobacter spp., Klebsiella spp., Citrobacter spp., Proteus spp., Serratia spp., Shigella spp., Yersinia spp., Salmonella spp. b Enterococcus spp., Enterococcus faecalis. c Pseudomonas spp., Flavimonas spp., Acinetobacter spp. d Staphylococcus saprophyticus, Staphylococcus epidermidis, Staphylococcus haemolyticus. e Staphylococcus aureus, Staphylococcus intermedius, Staphylococcus pseudointermedius. f Corynebacterium spp., Gardnerella vaginalis, Stenotrophomonas maltophilia, Morganella morganii, Gemella palaticanis, Chromobacterium violaceum, Sphingomonas paucimobilis, Pasteurella multocida.
Figure 1Number of infections by Malassezia spp. and Staphylococcus spp. isolated from skin and ear samples in dogs between 2016 and 2019.
Antibacterial susceptibilities in bacteria isolated from clinical samples of dogs (2016–2019).
| Bacteria |
| % Susceptible | MDR (%) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMK | AMC | AMP | CEX | ENO | GEN | TMS | DOX | TET | CIP | FLO | PEN | AMPS | CET | RIF | CEF | NEO | CHL | ERY | CFP | |||
|
| 183 |
|
|
|
|
|
|
|
|
|
|
| - |
| - | - |
|
| - | - | - | 18.6 |
| 90 |
|
|
|
|
|
|
|
|
|
|
|
|
| - | - |
| - |
|
| - | 20.0 | |
|
| 163 |
|
|
|
|
|
|
|
|
|
|
| - |
|
| - |
|
| - | - | - | 17.2 |
| Other * | 14 |
|
|
|
|
|
|
| - | - | - | - | - | - | - | - | - | - | - | - | - | 7.1 |
| 79 |
|
|
|
|
|
|
|
|
|
| - | - |
| - | - |
|
| - | - | - | 49.4 | |
|
| 101 |
|
|
|
|
|
|
|
|
|
| - | - |
| - | - |
|
| - | - | - | 10.9 |
|
| 104 |
|
|
|
|
|
|
|
|
|
| - | - | - | - | - | - | - | - | - | - | 19.2 |
|
| 160 | - |
|
|
|
|
|
|
| - |
| - | - | - | - |
|
|
| - | - | - | 16.9 |
|
| 406 |
|
|
|
|
|
|
|
|
|
| - | - |
| - | - |
| - | - | - |
| 16.7 |
| Streptococcus spp. | 16 |
|
|
|
|
|
|
| - |
| - | - | - | - | - | - |
|
| - | - | - | 12.5 |
AMK: Amikacina, AMC: Amoxicillin-clavulanate, AMP: Ampicillin, CEX: Cephalexin, ENO: Enrofloxacin, GEN: Gentamicin, TMS: Trimethoprim-sulfadiazine, DOX: doxycyclin, TET: Tetracycline, CIP: Ciprofloxacina, FLO: florfenicol, PEN: Penicillin, AMPS: Ampicillin sulbactam, CET: ceftiofur, RIF: Rifampicin, CEF: Cephalothin, NEO: Neomycin, CHL: Chloramphenicol, ERY: Erythromycin, CFP: Cefoperazone, MDR: Multi-drug resistant. (-) not determined. *Other: Corynebacterium spp., Gardnerella vaginalis, Stenotrophomonas maltophilia, Morganella morganii, Gemella palaticanis, Chromobacterium violaceum, Sphingomonas paucimobilis, Pasteurella multocida. Interpretation of colors: DARK BLUE: 0.1–1% very low resistance, BLUE: >1–10% low resistance, PURPLE: >10–20% moderate resistance, RED: >20–50% high resistance, Light Green: >50–70% very high resistance, Dark Green: >70% extremely high resistance.
Bacterial isolates from clinical samples from cats submitted to the Diagnostic Laboratory of the Faculty of Agrarian Sciences, University of Antioquia (2016–2019).
| Clinical Samples |
|
|
|
| Others | ||||
|---|---|---|---|---|---|---|---|---|---|
| % (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | ||
| Wound | 29 | 17.2 (7.6–34.5) | 10.3 (3.6–26.4) | 6.9 (1.9–21.9) | 6.9 (1.9–21.9) | 6.9 (1.9–22.0) | 44.8 (28.4–62.5) | 3.4 (0.6–17.2) | 3.4 (0.6–17.2) |
| Urine | 29 | 24.1 (12.2–42.1) | 6.9 (1.9–21.9) | 31 (17.3–49.2) | 13.8 (5.5–30.6) | 10.3 (3.6–26.4) | 13.8 (5.5–30.6) | 0 (0–11.7) | 0 (0–11.7) |
| Ear | 18 | 5.6 (1–25.7) | 5.6 (0.9–25.8) | 0 (0–17.6) | 5.6 (0.9–25.7) | 16.7 (5.8–39.2) | 66.7 (43.7–83.7) | 0 (0–17.6) | 0 (0–17.6) |
| Nasal cavity | 10 | 20 (5.7–50.9) | 10 (1.8–40.4) | 0 (0–27.7) | 0 (0–27.7) | 30 (10.8–60.3) | 30 (10.8–60.3) | 0 (0–27.7) | 10 (1.8–40.4) |
| Skin | 3 | 33.3 (6.14–79.23) | 33.3 (6.1–79.2) | 33.3 (6.1–79.2) | 0 (0–56.1) | 0 (0–56.1) | 0 (0–56.1) | 0 (0–56.1) | 0 (0–56.1) |
| Surgical | 2 | 0 (0–65.8) | 50 (9.5–90.5) | 0 (0–65.8) | 0 (0–65.8) | 0 (0–65.8) | 50 (9.5–90.5) | 0 (0–65.8) | 0 (0–65.8) |
| Abscess | 2 | 0 (0–65.8) | 0 (0–65.7) | 0 (0–65.8) | 0 (0–65.8) | 0 (0–65.8) | 50 (9.5–90.5) | 50 (9.5–90.5) | 0 (0–65.8) |
| Eyes | 1 | 0 (0–79.3) | 100 (20.6–100) | 0 (0–79.3) | 0 (0–79.3) | 0 (0–79.3) | 0 (0–79.3) | 0 (0–79.3) | 0 (0–79.3) |
aEnterobacter spp., Klebsiella spp., Citrobacter spp., Proteus spp., Serratia spp., Shigella spp., Yersinia spp., Salmonella spp. b Enterococcus spp., Enterococcus faecalis. c Pseudomonas spp., Flavimonas spp., Acinetobacter spp. d Staphylococcus saprophyticus, Staphylococcus epidermidis, Staphylococcus haemolyticus. e Staphylococcus aureus, Staphylococcus intermedius, Staphylococcus pseudointermedius. f Corynebacterium spp., Gardnerella vaginalis, Stenotrophomonas maltophilia, Morganella morganii, Gemella palaticanis, Chromobacterium violaceum, Sphingomonas paucimobilis, Pasteurella multocida.
Antibacterial susceptibilities in bacteria isolated from clinical samples of cats (2016–2019).
| Bacteria |
| % Susceptible | MDR (%) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMK | AMC | AMP | CEX | ENO | GEN | TMS | DOX | TET | CIP | FLO | CEF | |||
|
| 18 | - |
|
|
|
|
|
|
|
|
|
|
| 33.3 |
|
| 16 |
|
|
|
|
|
|
| - | - |
| - | - | 6.3 |
|
| 13 | - |
|
|
|
|
|
|
|
| - | - |
| 30.8 |
| Others | 13 | - | - | - | - | - | - | - | - | - | - | - | - | 7.7 |
|
| 13 |
|
|
|
|
|
|
| - | - | - | - | - | 0.0 |
| 11 | - |
|
| - |
| - |
|
|
| - |
| - | 18.2 | |
|
| 11 |
|
|
|
|
|
|
| - | - | - | - | - | 18.2 |
| 8 | - | - | - | - |
|
|
|
| - | - | - | - | 37.5 | |
|
| 5 | - |
|
|
| - | - | - | - | - |
|
| - | 40.0 |
| 2 | - | - | - | - | - | - | - | - | - | - | - | - | 0.0 | |
AMK: Amikacina, AMC: Amoxicillin-clavulanate, AMP: Ampicillin, CEX: Cephalexin, ENO: Enrofloxacin, GEN: Gentamicin, TMS: Trimethoprim-sulfadiazine, DOX: doxycyclin, TET: Tetracycline, CIP: Ciprofloxacina, FLO: florfenicol, CEF: Cephalothin. MDR: Multi-drug resistant. Other: Corynebacterium spp., Gardnerella vaginalis, Stenotrophomonas maltophilia, Morganella morganii, Gemella palaticanis, Chromobacterium violaceum, Sphingomonas paucimobilis, Pasteurella multocida. (-) not determined. Interpretation of colors: DARK BLUE: 0.1–1% very low resistance, BLUE: >1–10% low resistance, PURPLE: >10–20% moderate resistance, RED: >20–50% high resistance, Light Green: >50–70% very high resistance, Dark Green: >70% extremely high resistance.